Anmelden Kostenlos registrieren

IMV EPS

Was ist das EPS von IMV?

EPS von IMV, Inc. ist -0.67

Was ist die Definition von EPS?



Der Gewinn pro Aktie (EPS) ist der Anteil des Gewinns eines Unternehmens, der jeder im Umlauf befindlichen Stammaktie zugewiesen wird. Es wird der Verdünnung angepasst und über letzten zwölf Monate nachgerechnet.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. Preferred stock rights have precedence over common stock. Therefore, dividends on preferred shares are subtracted before calculating the EPS. When preferred shares are cumulative, annual dividends are deducted whether or not they have been declared. Dividends in arrears are not relevant when calculating EPS. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

EPS von Unternehmen in Health Care Sektor auf TSX im Vergleich zu IMV

Was macht IMV?

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

Unternehmen mit eps ähnlich IMV